Literature DB >> 22696051

Adoptive immunity mediated by HLA-A*0201 restricted Asp f16 peptides-specific CD8+ T cells against Aspergillus fumigatus infection.

Z Sun1, P Zhu, L Li, Z Wan, Z Zhao, R Li.   

Abstract

Aspergillus fumigatus (A. fumigatus) is the most common pathogen of invasive aspergillosis (IA), a life-threatening infection in immunocompromised patients. Recent findings revealed that CD8+ T cells can mediate cytotoxic activity against A. fumigatus. Here, we bioinformatically identified three HLA-A*0201-restricted peptides from Asp f16, an A. fumigatus antigen which was previously shown to be involved in T cell immunity. Our immunological results demonstrated that these peptides can potently induce cytotoxic T lymphocyte (CTL) response in CD8+ T cells, thus, damaging the conidia and hyphae of A. fumigatus. Moreover, the Asp f16 peptides can also raise Th1 cell-like response, as measured by interferon-γ (IFN-γ) enzyme-linked immunosorbent spot (ELISPOT). Furthermore, we established an invasive pulmonary aspergillosis model in HLA-A*0201 transgenic mice. Adoptive transfer of Asp f16 peptides-specific CTL significantly extended the overall survival time in the A. fumigatus-infected immunocompromised mice. In conclusion, our results demonstrate that the Asp f16 peptides might provide immunity against invasive A. fumigatus infection.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22696051     DOI: 10.1007/s10096-012-1670-2

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  25 in total

Review 1.  Aspergillosis. Pathogenesis, clinical manifestations, and therapy.

Authors:  Kieren A Marr; Thomas Patterson; David Denning
Journal:  Infect Dis Clin North Am       Date:  2002-12       Impact factor: 5.982

Review 2.  L-BLP25: a peptide vaccine strategy in non small cell lung cancer.

Authors:  Randeep Sangha; Charles Butts
Journal:  Clin Cancer Res       Date:  2007-08-01       Impact factor: 12.531

Review 3.  Trends in immunotherapy of fungal infections.

Authors:  B J Kullberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-01       Impact factor: 3.267

4.  Proteome of conidial surface associated proteins of Aspergillus fumigatus reflecting potential vaccine candidates and allergens.

Authors:  Abdul R Asif; Michael Oellerich; Victor W Amstrong; Birgit Riemenschneider; Michel Monod; Utz Reichard
Journal:  J Proteome Res       Date:  2006-04       Impact factor: 4.466

5.  T cell vaccination in mice with invasive pulmonary aspergillosis.

Authors:  E Cenci; A Mencacci; A Bacci; F Bistoni; V P Kurup; L Romani
Journal:  J Immunol       Date:  2000-07-01       Impact factor: 5.422

6.  Healthy human T-Cell Responses to Aspergillus fumigatus antigens.

Authors:  Neelkamal Chaudhary; Janet F Staab; Kieren A Marr
Journal:  PLoS One       Date:  2010-02-17       Impact factor: 3.240

7.  Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants.

Authors:  Silvia Bozza; Roberta Gaziano; Grayson B Lipford; Claudia Montagnoli; Angela Bacci; Paolo Di Francesco; Viswanath P Kurup; Hermann Wagner; Luigina Romani
Journal:  Microbes Infect       Date:  2002-11       Impact factor: 2.700

Review 8.  Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.

Authors:  Cornelis J M Melief; Sjoerd H van der Burg
Journal:  Nat Rev Cancer       Date:  2008-05       Impact factor: 60.716

9.  Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis.

Authors:  Carlos A Alvarez; Nathan P Wiederhold; Jason T McConville; Jay I Peters; Laura K Najvar; John R Graybill; Jacqueline J Coalson; Robert L Talbert; David S Burgess; Rosie Bocanegra; Keith P Johnston; Robert O Williams
Journal:  J Infect       Date:  2007-03-13       Impact factor: 6.072

10.  A novel Th cell epitope of Candida albicans mediates protection from fungal infection.

Authors:  Eva Bär; André Gladiator; Sonia Bastidas; Bernd Roschitzki; Hans Acha-Orbea; Annette Oxenius; Salomé LeibundGut-Landmann
Journal:  J Immunol       Date:  2012-04-23       Impact factor: 5.422

View more
  6 in total

Review 1.  Aspergillus vaccines: Hardly worth studying or worthy of hard study?

Authors:  Stuart M Levitz
Journal:  Med Mycol       Date:  2016-09-17       Impact factor: 4.076

Review 2.  Vaccine immunity against fungal infections.

Authors:  Som G Nanjappa; Bruce S Klein
Journal:  Curr Opin Immunol       Date:  2014-03-03       Impact factor: 7.486

Review 3.  Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells.

Authors:  Pappanaicken R Kumaresan; Thiago Aparecido da Silva; Dimitrios P Kontoyiannis
Journal:  Front Immunol       Date:  2018-01-08       Impact factor: 7.561

Review 4.  Rodent Models of Invasive Aspergillosis due to Aspergillus fumigatus: Still a Long Path toward Standardization.

Authors:  Guillaume Desoubeaux; Carolyn Cray
Journal:  Front Microbiol       Date:  2017-05-16       Impact factor: 5.640

Review 5.  Immunomodulation as Therapy for Fungal Infection: Are We Closer?

Authors:  Qi Hui Sam; Wen Shan Yew; Chaminda J Seneviratne; Matthew Wook Chang; Louis Yi Ann Chai
Journal:  Front Microbiol       Date:  2018-07-25       Impact factor: 5.640

Review 6.  The immune interplay between the host and the pathogen in Aspergillus fumigatus lung infection.

Authors:  Helioswilton Sales-Campos; Ludmilla Tonani; Cristina Ribeiro Barros Cardoso; Márcia Regina Von Zeska Kress
Journal:  Biomed Res Int       Date:  2013-07-30       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.